Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma

Z Zezhong Ye (Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA) R Reza Mojahed-Yazdi (Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA) A Anna Zapaishchykova (Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA) D Divyanshu Tak (Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA) M Maryam Mahootiha (Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA) J Juan Carlos Climent Pardo (Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA) J John Zielke Y Yining Zha (Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA) C Christian Guthier R Roy B. Tishler D Danielle N. Margalit J Jonathan D. Schoenfeld R Robert I. Haddad R Ravindra Uppaluri B Benjamin Haibe-Kains C Clifton D. Fuller (Division of Radiation Oncology, Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX) M Mohamed Naser B Barbara A. Burtness (Department of Medicine and Yale Cancer Center, Yale University School of Medicine and Yale Cancer Center, New Haven, CT) H Hugo J.W.L. Aerts (Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA) F Frank Hoebers (Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA) B Benjamin H. Kann

Abstract

PURPOSE Extranodal extension (ENE) is a biomarker in oropharyngeal carcinoma (OPC) but can only be diagnosed via surgical pathology. We applied an automated artificial intelligence (AI) imaging platform integrating lymph node autosegmentation with ENE prediction to determine the prognostic value of the number of predicted ENE nodes. MATERIALS AND METHODS We conducted a multisite, retrospective study of 1,733 OPC patients with pretreatment computed tomography who underwent definitive radiation therapy across three institutions. Malignant lymph nodes were segmented using a validated deep learning auto-segmentation model, and segmented lymph nodes were sequentially processed with a validated ENE prediction model to calculate number of nodes with AI-predicted ENE (AI-ENE) per patient. We evaluated associations of AI-ENE with disease outcomes using site-stratified, multivariable Cox regression, adjusting for human papillomavirus (HPV) status, smoking pack-years, tumor and nodal stage, age, and sex. We evaluated risk-stratification improvement when incorporating AI-ENE into the Radiation Therapy Oncology Group (RTOG)-0129 risk groupings and derived American Joint Committee on Cancer (AJCC) 8th edition staging with Uno C-indices and decision curve analyses. RESULTS Overall, median AI-ENE node number was 1 (range, 0-6). AI-ENE node number was independently associated with poorer distant control (DC; hazard ratio [HR], 1.44 [95% CI, 1.23 to 1.69]; P < .001) and overall survival (OS; HR, 1.30 [95% CI, 1.16 to 1.46]; P < .001). Increasing AI-ENE node number was incrementally associated with worse outcome, particularly DC ( P < .001). C-indices improved in the external data set when incorporating AI-ENE into RTOG-0129 groupings (OS: 0.70 v 0.65; DC: 0.65 v 0.57) and AJCC-8 stage (OS: 0.75 v 0.70; DC: 0.72 v 0.67; P < .001 for each). The largest improvements were observed among HPV-negative patients (C-index: +15% for OS, +14% for DC). CONCLUSION Automated, AI-ENE node number is a novel risk factor for OPC that may better inform pretreatment risk stratification and decision-making.

Article Details

Volume / Issue Vol. 44, Issue 5
Published February 10, 2026
Pages 386-399
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (21)

Z

Zezhong Ye

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA

R

Reza Mojahed-Yazdi

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA

A

Anna Zapaishchykova

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA

D

Divyanshu Tak

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA

M

Maryam Mahootiha

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA

J

Juan Carlos Climent Pardo

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA

J

John Zielke

Y

Yining Zha

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA

C

Christian Guthier

R

Roy B. Tishler

D

Danielle N. Margalit

J

Jonathan D. Schoenfeld

R

Robert I. Haddad

R

Ravindra Uppaluri

B

Benjamin Haibe-Kains

C

Clifton D. Fuller

Division of Radiation Oncology, Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX

M

Mohamed Naser

B

Barbara A. Burtness

Department of Medicine and Yale Cancer Center, Yale University School of Medicine and Yale Cancer Center, New Haven, CT

H

Hugo J.W.L. Aerts

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA

F

Frank Hoebers

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA

B

Benjamin H. Kann